Hatchtech appoints Tim Waugh as ceo

Formerly with Roche in the US as a divisional vice president

Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.

Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.

Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’

DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.

Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.

Waugh will join the Board of Hatchtech and will be based in New Jersey, US.

You may also like

Packaging

SmartSkin unveils pharma seal assurance solution with real-time insights

The breakthrough solution will give manufacturers real-time visibility into container closure integrity and capping performance, with SmartSkin aiming to debut the technology at the upcoming IPSE 4.0 in Barcelona
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Manufacturing

IDA Ireland releases whitepaper on the future of biopharma manufacturing in Ireland

The report highlights details on Ireland's geopolitical stability, its high regulatory standards and how the country is forging ahead as a leader in the advanced therapy and next-gen biologics sector
Pharma 5.0

Excelsior Sciences raises $95m for AI-powered small molecule discovery and manufacturing

Deerfield Management, Khosla Ventures and Sofinnova Partners co-lead Series A fundraising for Excelsior Sciences to accelerate drug discovery and clinical development while supporting pharma reshoring
Manufacturing

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Contamination Control

Eurofins launches first GMP-compliant PFAS screening solution for the medical device industry

Eurofins Medical Device Services North America has introduced the industry’s first GMP PFAS testing and screening platform, helping manufacturers meet tightening global regulations and safeguard device and patient safety
Subscribe now